Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality
European cytokine network, 2020•Springer
Abstract Coronavirus disease (COVID-19) reached pandemic proportions at the beginning
of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory
distress syndrome are the leading causes of death in severely or critically ill patients. The
elevated cytokine levels in severe patients in comparison with mildly affected patients
suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In
this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF …
of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory
distress syndrome are the leading causes of death in severely or critically ill patients. The
elevated cytokine levels in severe patients in comparison with mildly affected patients
suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In
this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF …
Abstract
Coronavirus disease (COVID-19) reached pandemic proportions at the beginning of 2020 and continues to be a worldwide concern. End organ damage and acute respiratory distress syndrome are the leading causes of death in severely or critically ill patients. The elevated cytokine levels in severe patients in comparison with mildly affected patients suggest that cytokine release syndrome (CRS) occurs in the severe form of the disease. In this paper, the significant role of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-alpha, and their mechanism of action in the CRS cascade is explained. Potential therapeutic approaches involving anti-IL-6 and anti-TNF-alpha antibodies to fight COVID-19 and reduce mortality rate in severe cases are also discussed.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果